< 1 min reading time There are rumours of potential changes to the FDA approval process particularly geared at devices processed through the 510(k) pathway. Will these changes affect reimbursement strategies? If so, how? Marked as spam |
Meet your next client here. Join our medical devices group community.
Please log in to post questions.